Display options
Cite
Gelhorn H, Balantac Z, Shinde S, et al. The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective. Diabetes Ther. 2021;12(7):1821-1837doi: 10.1007/s13300-021-01054-6.
Gelhorn, H., Balantac, Z., Shinde, S., Thieu, V. T., & Boye, K. S. (2021). The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective. Diabetes therapy : research, treatment and education of diabetes and related disorders, 12(7), 1821-1837. https://doi.org/10.1007/s13300-021-01054-6
Gelhorn, Heather, et al. "The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 12,7 (2021): 1821-1837. doi: https://doi.org/10.1007/s13300-021-01054-6
Gelhorn H, Balantac Z, Shinde S, Thieu VT, Boye KS. The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective. Diabetes Ther. 2021 Jul;12(7):1821-1837. doi: 10.1007/s13300-021-01054-6. Epub 2021 May 27. PMID: 34043162; PMCID: PMC8155797.
Copy Download .nbib Format: NLM
Share it on

Diabetes Ther. 2021 Jul;12(7):1821-1837. doi: 10.1007/s13300-021-01054-6. Epub 2021 May 27.

The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Heather Gelhorn, Zaneta Balantac, Shraddha Shinde, Vivian Thuyanh Thieu, Kristina S Boye

Affiliations

  1. Evidera Inc., 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, USA. [email protected].
  2. Evidera Inc., 7101 Wisconsin Ave, Suite 1400, Bethesda, MD, USA.
  3. Eli Lilly and Company, Indianapolis, IN, USA.

PMID: 34043162 PMCID: PMC8155797 DOI: 10.1007/s13300-021-01054-6

Abstract

INTRODUCTION: Type 2 diabetes (T2D) is extremely burdensome to people with T2D and associated with impaired health-related quality of life. This study explores the impact of T2D and potentially relevant outcomes for new therapies using a unique approach to in-depth qualitative interviews where people with T2D are asked to think about their future with T2D.

METHODS: A cross-sectional qualitative interview study among people with T2D from the USA and UK. Interviews explored their treatment journey, perceptions of their future with T2D, and the value of achieving normoglycemia (explored through presentation of two vignettes with hypothetical medications that reduced hemoglobin A1c [HbA1c] levels < 7% and < 5.7%).

RESULTS: Patients with T2D (N = 50; US n = 25; UK n = 25) were 66.0% male, had a mean body mass index (BMI) of 30.8 ± 6.3 kg/m

CONCLUSIONS: People with T2D have a high disease burden, a broad range of unmet needs, and extremely varied experiences and expectations on the impacts of T2D on their lives and future. Many patients indicated that achieving near normoglycemia would substantially change their lives primarily in terms of their physical and emotional health.

Keywords: Diabetes; Disease burden; HbA1c; Normoglycemia; Type 2 diabetes; Unmet needs

References

  1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: A growing challenge. N Engl J Med. 2007;356(3):213–5. - PubMed
  2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diab Care. 2004;27(5):1047–53. - PubMed
  3. World Health Organization (WHO). Diabetes: Global report on diabetes Geneva, Switzerland; 2016 [October 13, 2020]. 88 pgs. Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1 . - PubMed
  4. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. - PubMed
  5. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016;118(11):1723–35. - PubMed
  6. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–51. - PubMed
  7. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diab Care. 2011;34(6):1249–57. - PubMed
  8. Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7(3):231–40. - PubMed
  9. Kalyani RR, Golden SH, Cefalu WT. Diabetes and aging: unique considerations and goals of care. Diab Care. 2017;40(4):440–3. - PubMed
  10. Tabish SA. Is diabetes becoming the biggest epidemic of the twenty-first century? Int J Health Sci (Qassim). 2007;1(2):V–VIII. - PubMed
  11. Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. Rev Cardiovasc Med. 2003;4(Suppl 6):S3-10. - PubMed
  12. Ogunmodede AJ, Abiodun O, Makanjuola AB, Olarinoye JK, Ogunmodede JA, Buhari OI. Burden of care and psychological distress in primary caregivers of patients with type -2 diabetes mellitus in A tertiary hospital in Nigeria. Ethiop J Health Sci. 2019;29(6):697–708. - PubMed
  13. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205–18. - PubMed
  14. Cannon A, Handelsman Y, Heile M, Shannon M. Burden of illness in type 2 diabetes mellitus. J Manag Care Spec Pharm. 2018;24(9-a Suppl):S5–S13. - PubMed
  15. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82. - PubMed
  16. Beverly EA, Ritholz MD, Brooks KM, Hultgren BA, Lee Y, Abrahamson MJ, et al. A qualitative study of perceived responsibility and self-blame in type 2 diabetes: reflections of physicians and patients. J Gen Intern Med. 2012;27(9):1180–7. - PubMed
  17. Cimo A, Dewa CS. Symptoms of mental illness and their impact on managing type 2 diabetes in adults. Can J Diabetes. 2018;42(4):372–81. - PubMed
  18. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379–85. - PubMed
  19. American Diabetes Association (ADA). Standards of medical care in diabetes—2020 abridged for primary care providers. Clin Diabetes. 2020;38(1):10–38. - PubMed
  20. Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020;25(8). - PubMed
  21. Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–93. - PubMed
  22. Friese S, Ringmayr T. ATLAS.ti 8 User Guide and Reference. Berlin: ATLAS.ti Scientific Software Development GmBH; 2020. - PubMed
  23. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–88. - PubMed
  24. Willis GB. Analysis of the Cognitive Interview in Questionnaire Design. Understanding Qualitative Research. New York, NY: Oxford University Press; 2015. - PubMed
  25. Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391–409. - PubMed
  26. Litterbach E, Holmes-Truscott E, Pouwer F, Speight J, Hendrieckx C. 'I wish my health professionals understood that it's not just all about your HbA1c !'. Qualitative responses from the second Diabetes MILES - Australia (MILES-2) study. Diabetic Med. 2020;37(6):971–81. - PubMed
  27. Pal K, Dack C, Ross J, Michie S, May C, Stevenson F, et al. Digital health interventions for adults with type 2 diabetes: qualitative study of patient perspectives on diabetes self-management education and support. J Med Internet Res. 2018;20(2):e40. - PubMed
  28. St George SM, Pulgaron ER, Ferranti D, Agosto Y, Toro MI, Ramseur KC, et al. A qualitative study of cognitive, behavioral, and psychosocial challenges associated with pediatric type 2 diabetes in ethnic minority parents and adolescents. Diabetes Educ. 2017;43(2):180–9. - PubMed
  29. Tanenbaum ML, Kane NS, Kenowitz J, Gonzalez JS. Diabetes distress from the patient’s perspective: Qualitative themes and treatment regimen differences among adults with type 2 diabetes. J Diabetes Complications. 2016;30(6):1060–8. - PubMed
  30. Wardian JL, Tate J, Folaron I, Graybill S, True M, Sauerwein T. Who’s distressed? A comparison of diabetes-related distress by type of diabetes and medication. Patient Educ Couns. 2018;101(8):1490–5. - PubMed
  31. Jeong M, Reifsnider E. Associations of diabetes-related distress and depressive symptoms with glycemic control in Korean Americans with type 2 diabetes. Diabetes Educ. 2018;44(6):531–40. - PubMed
  32. Mishra A, Podder V, Modgil S, Khosla R, Anand A, Nagarathna R, et al. Higher perceived stress and poor glycemic changes in prediabetics and diabetics among Indian population. J Med Life. 2020;13(2):132–7. - PubMed
  33. Parsa S, Aghamohammadi M, Abazari M. Diabetes distress and its clinical determinants in patients with type II diabetes. Diabetes Metab Syndr. 2019;13(2):1275–9. - PubMed
  34. Ascher-Svanum H, Zagar A, Jiang D, Schuster D, Schmitt H, Dennehy EB, et al. Associations between glycemic control, depressed mood, clinical depression, and diabetes distress before and after insulin initiation: An exploratory. Post Hoc Anal Diabetes Ther. 2015;6(3):303–16. - PubMed
  35. Chen J, Fan L, Peng X, Ilag L, Ly T, Johnson J. Patient-reported outcomes in a study of human regular U-500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes. Diabetes Obes Metab. 2020. - PubMed
  36. Zhu L, Chandran SR, Tan WB, Xin X, Goh SY, Gardner DSL. Persistent anxiety is associated with higher glycemia post-transition to adult services in Asian Young adults with diabetes. Diabetes Metab J. 2020. - PubMed

Publication Types

Grant support